Bergenbio ASA (Norway) Performance
| BGBIO Stock | NOK 1.64 0.03 1.80% |
The firm shows a Beta (market volatility) of 0.99, which signifies possible diversification benefits within a given portfolio. Bergenbio ASA returns are very sensitive to returns on the market. As the market goes up or down, Bergenbio ASA is expected to follow. At this point, Bergenbio ASA has a negative expected return of -1.2%. Please make sure to confirm Bergenbio ASA's potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Bergenbio ASA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Bergenbio ASA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 721.6 M | |
| Total Cashflows From Investing Activities | 3.1 M |
Bergenbio |
Bergenbio ASA Relative Risk vs. Return Landscape
If you would invest 842.00 in Bergenbio ASA on December 22, 2024 and sell it today you would lose (678.00) from holding Bergenbio ASA or give up 80.52% of portfolio value over 90 days. Bergenbio ASA is generating negative expected returns and assumes 12.4091% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Bergenbio on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Bergenbio ASA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bergenbio ASA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bergenbio ASA, and traders can use it to determine the average amount a Bergenbio ASA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0967
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BGBIO |
Estimated Market Risk
| 12.41 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bergenbio ASA is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bergenbio ASA by adding Bergenbio ASA to a well-diversified portfolio.
Bergenbio ASA Fundamentals Growth
Bergenbio Stock prices reflect investors' perceptions of the future prospects and financial health of Bergenbio ASA, and Bergenbio ASA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bergenbio Stock performance.
| Return On Equity | -0.96 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (383.14) % | |||
| Current Valuation | 421.26 M | |||
| Shares Outstanding | 88.66 M | |||
| Price To Book | 3.92 X | |||
| Price To Sales | 756.59 X | |||
| Revenue | 774 K | |||
| EBITDA | (308 M) | |||
| Cash And Equivalents | 436.65 M | |||
| Cash Per Share | 5.59 X | |||
| Total Debt | 942 K | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 1.86 X | |||
| Cash Flow From Operations | (303.34 M) | |||
| Earnings Per Share | (3.50) X | |||
| Total Asset | 450.24 M | |||
About Bergenbio ASA Performance
By examining Bergenbio ASA's fundamental ratios, stakeholders can obtain critical insights into Bergenbio ASA's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bergenbio ASA is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. The company was founded in 2007 and is headquartered in Bergen, Norway. BerGenBio ASA is traded on Oslo Stock Exchange in Norway.Things to note about Bergenbio ASA performance evaluation
Checking the ongoing alerts about Bergenbio ASA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bergenbio ASA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bergenbio ASA generated a negative expected return over the last 90 days | |
| Bergenbio ASA has high historical volatility and very poor performance | |
| Bergenbio ASA may become a speculative penny stock | |
| Bergenbio ASA has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 774 K. Net Loss for the year was (309.36 M) with profit before overhead, payroll, taxes, and interest of 774 K. | |
| Bergenbio ASA has accumulated about 436.65 M in cash with (303.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of the company shares are held by company insiders |
- Analyzing Bergenbio ASA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bergenbio ASA's stock is overvalued or undervalued compared to its peers.
- Examining Bergenbio ASA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bergenbio ASA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bergenbio ASA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bergenbio ASA's stock. These opinions can provide insight into Bergenbio ASA's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Bergenbio Stock
Bergenbio ASA financial ratios help investors to determine whether Bergenbio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bergenbio with respect to the benefits of owning Bergenbio ASA security.